Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.42 |
| ▸ | ALPL | P05186 | 2/20 | 0.33 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.33 |
| ▸ | ALPG | P10696 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28866573 | 0.83 | ALPL (0.34) | ALPLPLAAALPG | |
| SCHEMBL2822834 | 0.81 | DGAT1 (0.38) | DGAT1ALPLPLAAALPG | |
| SCHEMBL1396117 | 0.80 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL31091884 | 0.80 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL19924651 | 0.80 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL111672 | 0.80 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL204155 | 0.79 | SMN1; SMN2 (0.46) | DGAT1 | |
| SCHEMBL22093251 | 0.79 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL22093263 | 0.78 | CPB1 (0.33) | DGAT1 | |
| SCHEMBL29956380 | 0.78 | DGAT1 (0.33) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025227145-A1 | BENZAMIDE COMPOUNDS FOR TREATMENT OF HERPES VIRUSES | ASSEMBLY BIOSCIENCES, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| WO-2025227148-A1 | BICYCLIC HETEROCYCLE COMPOUNDS FOR TREATMENT OF HERPES VIRUSES | ASSEMBLY BIOSCIENCES, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| WO-2024258591-A2 | NOVEL INHIBITORS OF HISTONE DEMETHYLASES AND COMPOSITIONS AND METHODS THEREOF | XIANG YIBIN (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | Benevolentai Cambridge Limited (GB) | 2024-10-17 | — | — | US | disclosed |
| CN-111587112-B | Rho-related inhibitors of coiled-coil-containing protein kinases | 卡德门企业有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
| EP-4204417-A1 | PROTEIN SECRETION INHIBITORS | Kezar Life Sciences (US) | 2023-07-05 | — | — | EP | disclosed |
| US-8729263-B2 | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2014-05-20 | — | — | US | disclosed |
| US-20140051672-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2014-02-20 | — | — | US | disclosed |
| WO-2014028459-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2014-02-20 | — | — | WO | disclosed |
| US-20130096113-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2013056070-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-20 | — | — | US | disclosed |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-20 | — | — | US | disclosed |
| US-8026265-B2 | Heterocycle substituted ketone derivatives as histone deacetylase (HDAC) inhibitors | Istituto de Ricerche di Biologia Molecolare P. Angeletti SpA. (IT) | 2011-09-27 | — | — | US | disclosed |
| WO-2011090935-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20100234374-A1 | Heterocycle Substituted Ketone Derivatives as Histone Deacetylase (HDAC) Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096113-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | FLT3, PDGFRB, PDGFRA | DGAT1 3769/4885ALPL 4140/4885PLAA 2290/4885 |
| US-20140051672-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, SF3B5 | DGAT1 4016/4885ALPL 3803/4885PLAA 1384/4885 |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | DGAT1 3535/4885ALPL 4550/4885PLAA 1556/4885 |
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | SI, SLC10A2, NOS3 | DGAT1 3630/4885ALPL 283/4885PLAA 4699/4885 |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, RPS6KA5 | DGAT1 4104/4885ALPL 4661/4885PLAA 4270/4885 |
| US-20100234374-A1 | Heterocycle Substituted Ketone Derivatives as Histone Deacetylase (HDAC) Inhibitors | HDAC1, HDAC7, HDAC4 | DGAT1 2264/4885ALPL 4330/4885PLAA 4803/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | DGAT1 4613/4885ALPL 4014/4885PLAA 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.